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background:  Moderate or severe aortic insufficiency (AI) after transcatheter aortic valve replacement (TAVR) with first generation devices 
increased acute and long-term mortality. Post-dilation in order to improve procedural outcome increased acute stroke rate. Second 
generation devices are designed to reduce the risk for relevant AI and offer more control regarding valve positioning. We compared the 
repositionable Lotus valve with the balloon-expandable Edwards Sapien 3 valve regarding acute and 30 days` outcomes.
methods:  We evaluated post-procedural AI, need for post-dilation, rate of permanent pacemaker implantation, and device success 
according to VARC criteria in 78 patients with severe aortic stenosis undergoing transfemoral TAVR.
results:  From January to June 2014 the repositionable Lotus valve (N=26) or the balloon-expandable Edwards Sapien 3 valve (N=52) 
were implanted. Selection of valve size was based on CT measurements of annulus, left ventricular outflow tract and sinotubular junction 
in combination with the distance to left and right coronary ostium. Measurements were done with a dedicated software (3mensio). Baseline 
CT data and clinical characteristics did not differ between groups. There was no moderate or severe AI, no need for post-dilation or use of 
a second valve. The rate of none or trace AI by echocardiography was 88% for the Lotus valve and 84% for the Edwards Sapien 3 valve 
(p=0.62). There were no death, stroke, annulus rupture or coronary obstruction. Device success according to VARC2 criteria was 96% and 
98% (p=0.61) and need for pacemaker implantation 38% and 8% (p<0.001), respectively.
Conclusion:  TAVR with the repositionable Lotus Valve System and the balloon-expandable Edwards Sapien 3 demonstrated similar acute 
and 30 days results. With both second generation TAVR devices there was no moderate or severe aortic insufficiency and no need for post-
dilatation. Device success was similar between groups while need for permanent pacemaker was significantly higher with the Lotus Valve.
